Last reviewed · How we verify
Drug-Eluting Embolic Bead — Competitive Intelligence Brief
phase 3
Drug-eluting embolic bead
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Drug-Eluting Embolic Bead (Drug-Eluting Embolic Bead) — Tehran University of Medical Sciences. Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Drug-Eluting Embolic Bead TARGET | Drug-Eluting Embolic Bead | Tehran University of Medical Sciences | phase 3 | Drug-eluting embolic bead |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Drug-eluting embolic bead class)
- Tehran University of Medical Sciences · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Drug-Eluting Embolic Bead CI watch — RSS
- Drug-Eluting Embolic Bead CI watch — Atom
- Drug-Eluting Embolic Bead CI watch — JSON
- Drug-Eluting Embolic Bead alone — RSS
- Whole Drug-eluting embolic bead class — RSS
Cite this brief
Drug Landscape (2026). Drug-Eluting Embolic Bead — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-eluting-embolic-bead. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab